glp 1 and libido Are Sexual Side Effects Emerging With GLP-1 Agonists? MTP 115: GLP-1 and Libido:

Implications from the study included that 8.9% of diabetic patients and 6.7% of obese patients on GLP-1 developed NAION compared to 1.8% and 0.8% respectively in those using other medications

Though launched five years after Semaglutide (in 2022), it achieved $3.84 billion in Q1 sales

Diabetes Complications 35, 107840

Any use for binge eating would be off-label and should be specialist-initiated with appropriate monitoring due to its stimulant properties and potential for misuse

Sitagliptin is a pglycoprotein substrate, but does not inhibit pglycoprotein mediated transport of digoxin

Sometimes it is waiting for a reason to